HANGZHOU, China, Oct. 24 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. , one of mainland China's leading pharmaceutical companies, today announced the Company will hold a press conference on Wednesday, November 1, 2006 at 3:00 PM CCT (2:00 AM EST) at Aida Pharmaceutical's headquarters in Hangzhou, China. The press conference will follow a seminar for invited scientists and doctors to discuss Phase I trial results of the Company's prospective cancer treatment, Rh-Apo2L, and Aida Pharmaceuticals' intention to commence Phase II and III trials. Mr. Jin Biao, Chairman of Aida Pharmaceuticals, along with Chinese government officials, will address the press.
Aida Pharmaceuticals' press conference will announce Phase I trial results for Rh-Apo2L, in addition to the planned timeline for Phase II and Phase III trials. Aida intends to conduct these trials in approximately twenty hospitals throughout mainland China, involving approximately three to four hundred participants. The Company intends to discuss in which hospitals the trials will take place during the press conference. Additionally, Aida management will announce the Company's intention to build a GMP certified manufacturing facility for the production of Rh-Apo2L.
Prior to the press conference, Aida Pharmaceuticals will hold a seminar for medical professionals from hospitals in mainland China, and interested scientists to discuss Phase I trial results. Participants will also learn the initial timeline for Phase II and Phase III trials. The trials are anticipated to take up to one year to complete and upon approval by the SFDA to be immediately followed by commercialization as previously announced.
Mr. Jin Biao, Chairman of Aida Pharmaceuticals and Shanghai Qiaer Biotechnology stated, "Rh-Apo2L is a potentially revolutionary genetic treatment for various forms of cancer and we are pleased to have this opportunity to provide an update to the press and the Chinese public to explain where we are in the research and development process of this break through treatment. Our intention is to fully disclose the results of our Phase I trial results, in addition to explain when, why and how we will conduct Phase II and Phase III trials for which we expect imminent approval from the SFDA. Rh-Apo2L may change the landscape for cancer treatment in China and we want the scientific community, in addition to the Chinese government and its people, to fully understand how we developed the treatment and how we believe it will change the way doctors treat cancer."
Aida's Hangzhou headquarters is located at 31 Dingjiang Road, Jianggan District, Hangzhou, CHINA 310016. For more information, please contact Bethany Tomich of Equity Performance Group at 617-723-1465. Following the press conference, the information presented will be available via Aida's website, http://en.aidapharma.com.
About Aida Pharmaceuticals:
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China.
Contact Information: Company: Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Bethany Tomich (617) 723-1465 bethany@equityperfgp.comhttp://www.equityperformancegroup.com Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995:
This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov.
Aida Pharmaceuticals, Inc.CONTACT: Bethany Tomich of Equity Performance Group, for AidaPharmaceuticals, +1-617-723-1465, bethany@equityperfgp.com
